References
- Feagan BG, Sy R. Epidemiology of inflammatory bowel disease. In: Lichtenstein GR, ed. The Clinician’s Guide to Inflammatory Bowel Disease. Thorofare, NJ: Slack, Inc., 2003:1-8
- Targan SR, Shanahan F. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams and Wilkins, 1994
- Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85
- Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2005;48:1997-2009
- Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-412
- Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009;33:854-62
- Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001;85:430-4
- Solem CA, Loftus EV, Tremaine WJ, et al. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004;99:97-101
- Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950-954
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
- Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
- Reinisch W, Sandborn WJ, Hommes D, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trail. Gut 2011;60:780-7
- Remicade [package insert]. Horsham, PA: Janssen Services, LLC, 2012
- Humira® Prescribing Information. Abbott Laboratories, 2012
- Sandborn WJ, Rutgeerts P, Feagan B, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60
- Analysource Online Web Site. http://www.analysource.com/. Accessed September 2012
- Wong BJ, Cifaldi MA, Sanjoy R, et al. Analysis of drug and administrative costs allowed by U.S. private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm 2011;17:313-20
- Centers for Medicare & Medicaid Services Web site. http://www.cms.gov/apps/physician-fee-schedule/search/search-results.aspx?Y=0&T=0&HT=1&. Accessed June, 2011
- Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting. Am J Ther 2006;13:502-6
- Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008;28:1230-9